7th Innate Killer Summit 2022

The innate cell therapy field is exploding as novel research charges through the clinic, proving its potential as a safe, efficacious, and cost-effective treatment.
Taking place next March in San Diego, the 7th Innate Killer Summit is your opportunity to forge new collaborations across pharma, biotech, and academia.

The Innate Killer Summit is your only technical, industry-focussed, end-to-end innate immune cell therapy meeting to explore frontiers in immunobiology, genetic modification, clinical translation, scalable manufacturing, cryopreservation, and CMC.

Join over 200 experts from Fate Therapeutics, Cytovia Therapeutics, NKarta Therapeutics, Sanofi, Takeda, GSK, and more, to advance the clinical and phase development of NK, Macrophage, γδT and NKT cell therapies for liquid and solid tumors.

Realize the therapeutic potential of the next wave of cell therapies and maximize their benefits for scalable application with greater transduction efficiency, lower CRS and cheaper production compared to T-cell approaches.

Website https://go.evvnt.com/958209-0?pid=176 
Tickets https://go.evvnt.com/958209-1?pid=176 
Brochure https://go.evvnt.com/958209-3?pid=176 
LinkedIn https://go.evvnt.com/958209-4?pid=176 

Prices:
Drug Developer Pricing - Conference + Pre-Conference Day USD 3798.00
Drug Developer Pricing - Conference Only USD 2999.00
Academic Pricing - Conference + Pre-Conference Day USD 3298.00
Academic Pricing - Conference Only USD 2499.00
Service Provider Pricing - Conference + Pre-Conference Day USD 4298.00
Service Provider Pricing - Conference Only USD 3499.00

Speakers: Thorsten Graef, CMO, Acepodia, Blake Aftab, CSO, Adicet Bio, Don Healey, CTO, Adicet Bio, Arndt Schottelius, CSO, Affimed, Heather Raymon, VP Early Development & Program Management, Artiva Bio, Abhishek Srivastava, Senior Director Immunology, Athenex, Emily Wilkinson, Beacon Adoptive Cell Lead Research Analyst, Beacon Targeted Therapies, Debora Barton, CMO, Carisma Therapeutics, Nicholas Boyd, CDO, Cartherics, Joseph Gold, VP Technical Operations, Catamaran Bio, Bradley Glover, EVP & CTO, Celularity, Jennifer Dashnau, Head of Analytical Development & Quality Control, Century Therapeutics, Melody Eble, VP Global Regulatory Affairs, Century Therapeutics, Christina Coughlin, CEO, Cytoimmune Therapeutics, Daniel Teper, CEO, Cytovia Therapeutics, Stanley Frankel, CMO, Cytovia Therapeutics, Wei Li, CSO, Cytovia Therapeutics, Rizwan Romee, Associate Professor of Medicine, Dana-Farber Cancer Institute, Gregory Fiore, CEO, Exacis Biosciences, Jode Goodridge, Associate Director, Fate Therapeutics, Raedun Clarke, Director Process Development, Fate Therapeutics, Marcel Zwaal, CEO, Gadeta, Yoshikazu Yonemitsu, CSO & CTO, Gaia BioMedicine, Oliver Nussbaumer, VP Immunology, Gammadelta Therapeutics, Jan Spanholtz, CSO, Glycostem, Volker Huppert, CDO, Glycostem, Austin Bigley, VP Research & Development, Indapta Therapeutics, Michael DeRidder, VP Medicine Commercialization Leader, Oncology Cell Therapy, GSK, Kate Rochlin, VP Operations & Innovations, IN8bio, Uriel Moreno, Scientist, Johnson & Johnson, Evren Alici, Head of Cell & Gene Therapy Group, Karolinska Institutet, Hans-Gustaf Ljunggren, Professor, Karolinska Institutet, Kimberly Schluns, Senior Director Research, Kite: A Gilead Company, Nicholas Huntington, Professor Biochemistry & Molecular Biology, Monash University, Emily Levy, Senior Scientist, Merck, James Trager, CSO, NKarta, Kanya Rajangam, CMO, NKarta Therapeutics, Ralph Brandenberger, SVP Tech Ops, NKarta Therapeutics, Stephen Chen, CTO, NKGen Biotech, Christopher Nowers, CEO, ONK Therapeutics, Mary Reilly, COO, ONK Therapeutics, Michael O’Dwyer, Founder & CSO, ONK Therapeutics, Stacey Cranert, Associate Director Research Immuno- Oncology, Poseida Therapeutics, Amy Sharma, Director Regulatory Toxicity, Strategy Lead Drug Safety R&D, Pfizer, Andre Kunert, Principal Scientist, Sanofi, Marcia Blackmoore, CMC Project Leader, Genomic Medicines Unit, Sanofi, Robert Igarashi, VP Discovery & Preclinical Development, Sanofi, Alba Gonzalez, Director of Research, Senti Biosciences, Gary Lee, CSO, Senti Biosciences, Philip Lee, CTO, Senti Biosciences, Daniel Kaufman, Co-Founder & CSO, Shoreline Biosciences, Aman Singh, Associate Director Clinical Pharmacology M&S, Cell Therapy, Takeda, Anahid Jewett, Professor & Director Tumor Immunology Laboratory, UCLA, Emily Mace, Assistant Professor of Pediatric Immunology, University of British Columbia, Beau Webber, Assistant Professor, University of Minnesota, Jeffrey Miller, Professor of Medicine, University of Minnesota, Branden Moriarity, Principal Investigator, University of Minnesota, Caimei Zhang, Senior Research Investigator, University of Pennsylvania, Neil Sheppard, Adjunct Associate Professor, University of Pennsylvania, Christian Capitini, Associate Professor, Pediatrics, University of Wisconsin-Madison, Todd Fehniger, Professor of Medicine, Washington University School of Medicine, St. Louis, Ayman Kabakibi, COO, Wugen, Daniel Kemp, CEO, Wugen, Michael Uhlin, CSO, XNK Therapeutics, Anders Holm, COO, Zelluna Immunotherapy

Date and Time: Starts: Wed, Mar 30, 2022 ( 8:30 AM) and Ends: Fri, Apr 1, 2022 ( 5:45 PM)

Venue details: Sheraton San Diego Hotel & Marina